Time to surgery after completion of neoadjuvant chemotherapy does not negatively impact recurrence and survival outcomes in breast cancer patients.
Schin BekRehena SultanaSherry De Xuan DuQing Ting TanPublished in: World journal of surgery (2024)
Time to surgery after completion of neoadjuvant chemotherapy did not appear to affect recurrence or survival outcomes. Findings from this study may allow more flexibility and reduce the burden of scheduling patients for surgery within the usual four-to-eight-week window in centers with resource and scheduling constraints.
Keyphrases
- neoadjuvant chemotherapy
- minimally invasive
- locally advanced
- coronary artery bypass
- lymph node
- sentinel lymph node
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- rectal cancer
- squamous cell carcinoma
- radiation therapy
- clinical trial
- early stage
- acute coronary syndrome
- coronary artery disease
- percutaneous coronary intervention
- risk factors
- peritoneal dialysis
- atrial fibrillation